Abstract |
102 patients with AML ( leukemia after preleukemia, 2nd neoplasia included) were treated for remission induction by a modified TAD regimen in Munster; 55 patients (54%) achieved a complete remission (CR). For CR maintenance 40 patients were eligible for randomization according to the study protocol: cyclic chemotherapy (CT) alone vs. chemoimmunotherapy ( CIT: plus allogeneic Neuraminidase-treated blasts in high dosage). 5 CR patients, induced identically in Essen, were randomized additionally. Evaluating all patients randomized there is only a marginally beneficial effect of CIT (21 patients) compared to CT (24 patients) concerning median survival (1020+ vs. 612 days) and relapse-free survival (494 vs. 380 days) until now. For patients receiving more than 2 cycles of maintenance therapy, however, CIT prolongs relapse-free survival significantly (930+ vs. 409 days; p = 0,02); that is also true for remission duration. This suggests that only repeated application of blasts may induce an immune response leading to a biologically relevant antileukemic effect.
|
Authors | D Urbanitz, H J Pielken, P Koch, T Büchner, W Hiddemann, A Heinecke, F Wendt, G Maschmeier, J van de Loo |
Journal | Onkologie
(Onkologie)
Vol. 8
Issue 3
Pg. 157-9
(Jun 1985)
ISSN: 0378-584X [Print] Switzerland |
PMID | 3895098
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cytarabine
- Cyclophosphamide
- Thioguanine
- Daunorubicin
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bone Marrow Transplantation
- Combined Modality Therapy
- Cyclophosphamide
(administration & dosage)
- Cytarabine
(administration & dosage)
- Daunorubicin
(administration & dosage)
- Drug Administration Schedule
- Humans
- Immunotherapy
- Leukemia, Myeloid, Acute
(drug therapy, mortality, therapy)
- Prospective Studies
- Random Allocation
- Thioguanine
(administration & dosage)
|